EP Patent

EP4295853A3 — Formulations of brincidofovir

Assigned to Emergent Biodefense Operations Lansing Inc · Expires 2024-03-06 · 2y expired

What this patent protects

Disclosed are formulations comprising brincidofovir. The formulations can be intravenous formulations. The formulations can be used in cases where a subject experiences gastrointestinal issues in response to oral administration of brincidofovir. The formulations can also be used …

USPTO Abstract

Disclosed are formulations comprising brincidofovir. The formulations can be intravenous formulations. The formulations can be used in cases where a subject experiences gastrointestinal issues in response to oral administration of brincidofovir. The formulations can also be used in cases where oral administration of drug is not possible due to underlying conditions or concern around inadequate oral absorption.

Drugs covered by this patent

Patent Metadata

Patent number
EP4295853A3
Jurisdiction
EP
Classification
—
Expires
2024-03-06
Drug substance claim
No
Drug product claim
No
Assignee
Emergent Biodefense Operations Lansing Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.